Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity

A publication (journal article) of the University of Göttingen

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Efficacy of venlafaxine extended release in major depressive disorder patients: ​effect of baseline anxiety symptom severity​
Lyndon, G. J.; Prieto, R.; Wajsbrot, D. B.; Allgulander, C. & Bandelow, B.​ (2019) 
International Clinical Psychopharmacology34(3) pp. 110​-118​.​

Documents & Media

License

Published Version

Attribution-NonCommercial-NoDerivs 4.0 CC BY-NC-ND 4.0

Details

Authors
Lyndon, Gavin J.; Prieto, Rita; Wajsbrot, Dalia B.; Allgulander, Christer; Bandelow, Borwin
Abstract
Effects of baseline anxiety on the efficacy of venlafaxine extended release versus placebo were examined in a post hoc pooled subgroup analysis of 1573 patients enrolled in eight short-term studies of major depressive disorder. Anxiety subgroups were defined based on baseline 17-item Hamilton Rating Scale for Depression Item 10 score <3 (low) versus ≥3 (high). Change from baseline to final visit in Montgomery-Åsberg Depression Rating Scale total score and Montgomery-Åsberg Depression Rating Scale response and remission rates were analyzed. Change from baseline in Montgomery-Åsberg Depression Rating Scale total score and response and remission rates was significantly greater for venlafaxine extended release versus placebo in both low and high anxiety subgroups (all P < 0.0001). A statistically significant baseline anxiety by treatment interaction was observed for Montgomery-Åsberg Depression Rating Scale total score only (P = 0.0152). The adjusted mean change from baseline in Montgomery-Åsberg Depression Rating Scale total score was significantly greater in the high anxiety subgroup versus low anxiety subgroup for patients treated with venlafaxine extended release (-6.27 versus -3.89; P = 0.0440) but not placebo. These results support the efficacy of venlafaxine extended release for major depressive disorder treatment in patients with anxiety symptoms.
Rights
CC BY-NC-ND 4.0
Issue Date
2019
Document Version
Published Version
Journal
International Clinical Psychopharmacology 
ISSN
1473-5857; 0268-1315

Reference

Citations


Social Media